Conformation Rules Part 3: News, Common Threads, Debate from San Diego Protein Misfolding Conference
Ana Maria Cuervo
Randolph Hampton of University of California, San Diego, introduced the audience to his lab’s work on quality control pathways, which serve to regulate cellular protein levels by proteasome degradation. As an example, Hampton described regulated degradation of HMG-CoA reductase (HMGR), an enzyme in the cholesterol pathway. His lab discovered a natural case of the cell’s use of quality control to set its levels. In this case, in vivo levels of the pathway molecule farnesylpyrophosphate (FPP) determine degradation rates of HMGR. This process itself is modulated by chemical chaperones that stabilize HMGR and decrease access of the requisite E3 ligase, as well as by an FPP derivative that alters the folding state of HMGR to increase access by E3, Hampton said. This work shows that small molecules can affect a protein’s entry into a quality control pathway (see also Shearer et al., 2004).
The underlying mechanism might lead to a therapeutic strategy if drugs could be found that accelerate the recognition of misfolded disease protein by the cells’ quality control, Hampton said. Others in the audience noted that therapies that increase protein turnover generally, such as pathways stimulated by caloric restriction, might prove as useful as protein-specific interventions. That’s in part because the relative contribution of accumulation of specific misfolded proteins and proteasome dysfunction to pathogenesis remains unclear. Moreover, degenerative diseases of aging may well bring with them a broader rise in the level of proteins that need disposal, of which those that researchers know merely represent the tip of the iceberg.
Paul Muchowski tied chaperones into the growing recognition that large protein aggregates may be a lesser culprit in neurodegenerative diseases than early assemblies, however elusive they may be in vivo. He started out by noting that today’s version of the amyloid hypothesis—protein misfolding leads to amyloids, and somewhere along the process the cell dies—applies to many neurodegenerative diseases. Muchowski, who is at the University of Washington, Seattle, asked where in this process chaperones have their greatest effect. He chose to study aggregation of glutamine-expanded (polyQ) huntingtin, which in Huntington disease forms amyloid-like inclusions in the cytoplasm and the nucleus of affected neurons in the striatum and cortex.
Attention began shifting away from inclusions when it turned out that chaperones can prevent neurodegeneration in Drosophila, and also slow neuropathology and motor symptoms in a mouse model of spinocerebellar ataxia, all while leaving inclusions abundantly in place (Kazemi-Esfarjani and Benzer, 2000; Cummings et al., 2001). “This surprised everyone,” Muchowski recalled. It was perplexing, too: If chaperones prevent aggregation, but aggregation visibly occurs in these chaperone-treated models, then how did the chaperones pull off their beneficial effect?
Muchowski hypothesized that mutant huntingtin forms spherical or annular oligomers, and that chaperones prevent their accumulation. The researchers developed a system of controlled expression of the first exon of mutant huntingtin, and added chaperones at various time points in the aggregation process in a five-hour experiment. Spotting the mixture on a grid, they used atomic force microscopy to image and quantify what sorts of species had formed, according to how Brian Caughey and Peter Lansbury had described them for Aβ and a-synuclein. Muchowski’s team saw spherical assemblies form at concentrations well below the threshold for fiber formation; little rings formed at slightly higher concentrations, and fibers appeared above the threshold concentration. When the scientists added the chaperones Hsp40/70 right after turning on mutant ht expression, the oligomers never appeared but instead more fibers formed. Adding the chaperones even an hour into the process had no effect, indicating that chaperones act early in the aggregation process. The data appeared online last month (Wacker et al., 2004).
It’s not clear exactly what the chaperones do, but Muchowski speculates that by simply stabilizing the huntingtin monomer, they cover up certain binding sites needed for the oligomer pathway. One other thing: Muchowski suspects that oligomer formation may represent an offshoot from huntingtin’s major fiber-forming pathway. “It’s not clear at all that oligomers lead to fibers,” he said. This jibes with the observation that reducing oligomer formation actually leads to more fibers, not fewer, and with the finding that chaperones prevent toxicity but not fiber formation in the animal.
The larger question of whether large aggregates are toxic or a protective response by the cell received intense discussion, fueled by Steven Finkbeiner’s recent demonstration that inclusions helped cultured cells loaded with mutant huntingtin survive (see ARF related news story). “The aggregates are a red herring,” said Coleman. “They are there and we can see them. This has been the history with AD ever since Alois Alzheimer described the plaques and tangles. It may turn out that they are not the problem but earlier changes are, and that may be true with other aggregates. They are markers of something else that already happened.”
Therapeutic entry points from this research would appear obvious: Find ways to increase chaperone expression! Indeed, a compound that induces chaperones slows ALS in an SOD mouse model (Kieran et al., 2004), as did a genetic approach in a model of Parkinson’s (Auluck et al., 2002). The hitch, Muchowski said, is that chaperones do more than stabilize aberrant protein monomers. Much like the proteasome, they are prominent players in varied cellular processes. In particular, their role in signal transduction can create a kind of tug of war between neurodegeneration and proliferation. In some cancers, chaperones are overly active, and chaperone inhibition is indeed used in cancer treatment. Therefore, HSP activators would have to be specific and carefully targeted.
One of the many other functions of chaperones that are drawing intense interest in neurodegeneration research is their role in autophagy. By this process the cell degrades waste proteins inside its lysosomes, and it functions in parallel with the ubiquitin-proteasome system. Two complementary talks offered context and new data. First, Ana Maria Cuervo, of Albert Einstein College of Medicine in New York, explained that chaperone-mediated autophagy (CMA) is the most selective of the three known forms of autophagy. The other two major classes of lysosomal protein degradation are macroautophagy, which is inducible and chews up entire organelles, and its constitutively active cousin microautophagy. Both degrade cytosolic components sequestered inside vesicles that are created either de novo in the cytosol (macroautophagy) or pinched off from the lysosome membrane (microautophagy). By contrast, CMA destroys specific cytosolic proteins that translocate across the lysosomal membrane via the lamp2a receptor on the lysosome. Once proteins are inside the lysosome, they are gone within five minutes, but only proteins that carry the “kferq” recognition motif make it there. APP, huntingtin, and α-synuclein all have the kferq motif, and the cytosolic chaperone Hsp70 mediates their recognition and binding to lamp2a, Cuervo said.
Hypothetical model for the role of altered CMA in familial forms of Parkinson's disease Normal α-synuclein is eliminated from the cytosol through CMA after being recognized by a cytosolic chaperone. Mutant forms of α-synuclein are targeted to the lysosomal membrane and bind to the receptor but do not translocate. The high affinity of the mutant protein for the lysosomal receptor results in blockage of the translocation complex for other CMA substrates, that are likely to also accumulate in the cytosol of the affected cells.
Cuervo first outlined a series of experiments suggesting that CMA participates in the removal of damaged proteins. It responds to starvation, toxins, and oxidative stress in a variety of different cell types. Lysosomes isolated from cultured cells put under mild oxidative stress, or from mice injected with the toxin paraquat, both contained increased numbers of oxidized cytosolic proteins. Oxidized proteins translocate better into lysosomes, perhaps because they partially unfold, and CMA responds to paraquat stress by boosting the lysosomes’ capacity to import oxidized proteins.
With aging, CMA activity decreases while levels of oxidized cytosolic proteins increase. Cuervo suggested that the former contributes to the latter, and that CMA is where aging cells became particularly vulnerable to oxidative and toxic stress. To begin testing this assumption, the researchers interfered with lamp2a expression in fibroblasts. This led to oxidized proteins’ being stuck outside lysosomes and impaired the cells’ ability to survive conditions of oxidative and toxic stress.
Cuervo’s lab then set out on a foray into neurodegeneration by studying α-synuclein’s behavior on lysosomes (see ARF related news story). In a nutshell, the scientists show that both of the two α-synuclein mutations known to cause Parkinson disease bind more tightly than wild-type α-synuclein to the lysosomal lamp2a receptor, but they never enter the vesicles inside. In this way, mutant α-synuclein sticks around, and lysosomal receptors remain loaded so that other substrates cannot enter for their degradation, either. “As a consequence of CMA blockage, damaged proteins accumulate in the cytosol, and the cell loses its ability to respond to stress,” Cuervo said.
Cuervo’s work offers opportunities for collaboration with other labs working on neurodegeneration, particularly by way of cross-breeding her new line of mice. Cuervo and colleagues made a strain of mice, still young, in whom they can induce overexpression of lamp2a at will. They plan to activate lamp2a when the mice age and ask whether putting more receptors into lysosomes can prevent the age-related decrease in CMA, or even reverse the age-related accumulation of damaged proteins. Other future work will be directed at studying differences between oligomeric forms of α-synuclein and their effect on the lysosomal membrane (see Yang et al., 1008). Cuervo also plans to investigate the major AD risk factor ApoE, whose isoforms are known to differ in their lysosomal degradation (see Mahley section of ARF related news story, Yi et al., 2002).
Cuervo emphasized that researchers should not focus on one cellular degradation system exclusively. In her experience, experiments manipulating CMA lead to changes in other degradation systems, as well, as these systems crosstalk. For example, chronically blocking CMA in cultured cells leads, paradoxically, to an increase in overall degradation. That’s because macroautophagy kicks in to compensate, and proteasomal degradation also responded by changing the subunit composition of the proteasome. “Proteasomal degradation clearly crosstalks with lysosomal degradation, and this is why there is so much confusion in the proteasome field. This crosstalk is very important. We need to consider all these pathways and learn how they interact,” Cuervo said.
Ralph Nixon began his talk by seconding Cuervo’s appeal that scientists studying a given cellular protein degradation system always keep an eye on the others. He then focused on broader changes in autophagy in AD. In this disease, the lysosomal system becomes mobilized early on as a protective response, but it fails to pull all the way through to protein degradation and instead gets backed up somewhere in the process. This leads to pathologies that deserve more study, Nixon said. Bob Terry described accumulating lysosomes in AD (Suzuki and Terry, 1967), but this observation has been forgotten. “Now we realize how prominent this is,” Nixon said.
Autophagy begins with the formation of membrane sacs called autophagosomes, which then fuse with late endosomes or lysosomes for degradation of their contents. In normal brain this process is barely detectable, but most neurons in AD show evidence of it and do so with a massive pathology, Nixon said. Using antibodies that detect induction of autophagy, Nixon’s group saw an upregulation of the process in dendrites of hippocampus and cortex of PS/APP-transgenic mice that begins at nine weeks, before the mice deposit amyloid. By nine months, when amyloid deposition is in full swing, the autophagy antibody labels the dystrophic neurites known to course through and around plaques. In fact, autophagic vacuoles (AVs) become the predominant organelle in dystrophic neurites.
What stimulates this? Experimentally, sublethal Aβ levels and oxidative stress both induce autophagy in cultured neurons, Nixon said. What’s more, he believes that the presenilin protein may have a normal function in autophagy. Nixon’s collaborator Anne Cataldo, now at McLean Hospital in Belmont, found that FAD presenilin mutations cause a more severe disturbance of lysosome function than is seen in sporadic AD, and APP/PS double-transgenic mice have more pronounced lysosomal pathology than do mice transgenic for APP alone, (Cataldo et al., 2004). Fibroblasts from people with PS1 mutations showed a proliferation of AVs and kept accumulating them, unable to complete protein degradation, Nixon said. Blastocysts from PS1/2 double-knockouts failed to induce autophagy, leading Nixon to suggest that presenilin is required for autophagy. This suggests a presenilin function that is independent of APP cleavage but would be required for the clearance of amyloid through the lysosomal pathway, not to mention the many other proteins and organelles turned over by autophagy. It is unclear which presenilin substrate is required for autophagy to work properly. Since in FAD, autophagosomes accumulate and, in PS-null blastocysts, grow to “monster” proportions, Nixon said, it is likely to be one that comes into play later, perhaps during lysosome fusion.
Nixon also noted evidence that the components required for Aβ production are enriched in isolated AVs (Yu et al., 2004), suggesting that these autophagic organelles might continuously produce intraneuronal Aβ as they accumulate. “Peripherally, we have evidence that autophagy is a route for Aβ production,” Nixon said. Tau pathology also stimulates autophagocytosis, but Nixon questioned whether this process is an early manifestation of AD. Rather, tau dysfunction may tie autophagy and axonal transport into a broader picture.
What, then, is the earliest insult that promotes Aβ generation and, in turn, autophagy? No consensus pathway exists, but Nixon pointed to dysfunction in neuronal endocytosis as his favorite suspect. In this scenario, early endosomes do not mature and instead enlarge (Cataldo et al., 2004). Signaling endosomes do not travel to the nucleus to transmit protective growth factor signals, tying axonal transport into the picture (see also ARF related conference story).
Picking up the baton where Nixon had left off, Cynthia McMurray, in a rapid-fire presentation on Huntington disease (HD), concurred that defects in endocytosis are the earliest sign of trouble her experiments are picking up. To set the stage, McMurray, who is at the Mayo Clinic in Rochester, Minnesota, first recapped that while some molecular processes of HD overlap with those in other neurodegenerative diseases, HD's genetics are unusual. The defect is not a missense mutation or deletion, but an expansion of CAG triplet repeats, and the length of the expansion determines age of onset. Curiously, the length of the expansion grows from generation to generation, such that the disease can begin at age 50 in a grandfather, 26 in his daughter, and six months in her child, reflecting a lengthening of the repeats from 92 in the first generation to over 200 in the third.
A thumbtack version of McMurray’s view of Huntington’s goes like this: Toxicity arises from an oxidation cycle that couples htt protein and DNA. Mutant huntingtin first causes defects in endosome and axonal trafficking. This impairs mitochondria, which then secrete toxic radicals. The radicals modify DNA, and subsequent attempts to repair the damage create DNA breaks, which lead to somatic expansion of the CAG repeat. In this cycle, the trafficking defect sets off toxicity, and the oxidative/DNA damage cycle continues throughout life. Inclusions form as a consequence of the critical toxic events, McMurray contends.
McMurray’s experiments use mice and cultured striatal neurons expressing full-length mutant human huntingtin (mhtt). “All my work uses the endogenous whole protein. I don’t think expressing just an exon or two gives you the right answer,” McMurray said. Early on in her studies, the cultured neurons retracted their axons within two days of expressing mhtt because traffic along microtubules faltered. A closer look revealed that the first step in this defective process lay in little flask-shaped indentations of the cell membrane called caveolae that were not being properly endocytosed and trafficked anymore. Found in most tissues, caveolae constitute a system of endocytic transport vesicles that operates alongside the better-known clathrin-coated pits. They remain enigmatic but are of particular intrigue in neurodegenerative disease because their constituent proteins, the caveolins, also serve as scaffolding hubs that recruit signaling molecules to the caveolae. This is important for the function of signaling endosomes and has been implicated in Parkinson disease (Hashimoto et al., 2003).
McMurray found that caveolin protein interacts strongly with the mutant htt, but not with normal htt. This weakens caveolin’s required interaction with cholesterol. Caveolae from the mutant htt-expressing neurons were unable to efflux cholesterol from the neurons, and cholesterol piled up inside them. This observation held in vivo, as the scientists correlated large intraneuronal increases in cholesterol with the appearance of a clasping motor phenotype in HD mice. In culture, turning mutant htt expression on induced a cholesterol increase, and silencing the gene restored proper trafficking of caveolae and brought cholesterol levels down, McMurray said. She suspects that this cholesterol accumulation compromises the nuclear membrane in such a way that huntingtin—otherwise too large a protein to enter the nucleus under normal conditions—can now enter. Even so, McMurray attributes all the changes leading up to this nuclear translocation to htt in the cytoplasm and contended that nuclear htt has little to do with the primary pathophysiology of HD (see also ARF related news story). “I really think nuclear aggregation is a late event,” McMurray said.
Caveolar membranes are of the lipid raft type, and McMurray’s team is now studying how their lipid content changes. This finding has echoes in other neurodegenerative diseases where altered cholesterol homeostasis is a problem. For example, Niemann-Pick syndrome is primarily a disease of cholesterol storage in lysosomes, and ApoE, which receives cholesterol from caveolae, is a risk factor in AD.
The early endocytic problems then grow into broader trafficking defects along microtubules. Mitochondria in htt-mutant mice stop moving even before neurological symptoms develop, probably because mutant htt sequesters wild-type htt along with motor proteins and other trafficking components. This work, recently published (Trushina et al., 2004), confirms in mammals earlier work done in invertebrates (see ARF related news story).
A second line of investigation traces what happens to the cell after damaged mitochondria begin spewing out hydroxyl radicals. McMurray said she believed that the obvious consequence—protein and lipid oxidation—wreaks less havoc than what goes on at the DNA. There, hydroxyl radicals launch a process that leads to a cycle of lengthening of the repeat size and aggravated htt toxicity in a given person as (s)he ages, McMurray contends.
The growth of the htt expansion can be shown in HD mice and in humans. To test the idea that hydroxyl radicals instigate it, McMurray and colleagues isolated embryonic cells from their HD mice and treated them with hydrogen peroxide. This prompted the existing triplet repeats to lengthen with time. Further studies detailed a process by which the DNA repair enzyme 8-oxoG-DNA glycosylase (OGG1) cuts out oxidized bases from the DNA, creating a strand break. In their experiments, this strand lifted off the DNA duplex and formed a stable loop with itself, leaving behind a single-stranded gap that DNA polymerases subsequently filled in. Also left behind was a longer expansion in the aberrant loop. It gets transcribed to yield a more toxic htt protein, and it provides more spaces for oxidation and further elongation with age. This process was more active in brain than in liver, McMurray noted. To test this model, the scientists bred mice lacking the OGG1 enzyme with mice expressing mutant htt, and the crosses indeed do not show repeat expansion with age. Preliminary data suggest that the crosses develop a milder form of disease, as well, McMurray said.—Gabrielle Strobel.
- New Microscope Resolves Role of Huntington Inclusions—Neuroprotection
- Lysosomes and Proteasomes Compete for PD Researchers' Attention
- ApoE Primer: News on Sulfatide and Insulin Links, Synaptic Damage and Molten Globules
- San Diego: Too Much APP Blocks Transport, Starves Down's Neurons
- Reality TV: Watching Huntingtin in Action
- Huntington’s Protein Snarls Axonal Traffic
- Conformation Rules Part 1: News, Common Threads, Debate from San Diego Conference
- Conformation Rules Part 2: News, Common Threads, Debate from San Diego Protein Misfolding Conference
- Shearer AG, Hampton RY. Structural control of endoplasmic reticulum-associated degradation: effect of chemical chaperones on 3-hydroxy-3-methylglutaryl-CoA reductase. J Biol Chem. 2004 Jan 2;279(1):188-96. PubMed.
- Kazemi-Esfarjani P, Benzer S. Genetic suppression of polyglutamine toxicity in Drosophila. Science. 2000 Mar 10;287(5459):1837-40. PubMed.
- Cummings CJ, Sun Y, Opal P, Antalffy B, Mestril R, Orr HT, Dillmann WH, Zoghbi HY. Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice. Hum Mol Genet. 2001 Jul 1;10(14):1511-8. PubMed.
- Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci. 2003;26:267-98. PubMed.
- Wacker JL, Zareie MH, Fong H, Sarikaya M, Muchowski PJ. Hsp70 and Hsp40 attenuate formation of spherical and annular polyglutamine oligomers by partitioning monomer. Nat Struct Mol Biol. 2004 Dec;11(12):1215-22. PubMed.
- Kieran D, Kalmar B, Dick JR, Riddoch-Contreras J, Burnstock G, Greensmith L. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med. 2004 Apr;10(4):402-5. PubMed.
- Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science. 2002 Feb 1;295(5556):865-8. PubMed.
- Yang AJ, Chandswangbhuvana D, Margol L, Glabe CG. Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Abeta1-42 pathogenesis. J Neurosci Res. 1998 Jun 15;52(6):691-8. PubMed.
- Ji ZS, Miranda RD, Newhouse YM, Weisgraber KH, Huang Y, Mahley RW. Apolipoprotein E4 potentiates amyloid beta peptide-induced lysosomal leakage and apoptosis in neuronal cells. J Biol Chem. 2002 Jun 14;277(24):21821-8. PubMed.
- Suzuki K, Terry RD. Fine structural localization of acid phosphatase in senile plaques in Alzheimer's presenile dementia. Acta Neuropathol. 1967 May 5;8(3):276-84. PubMed.
- Cataldo AM, Peterhoff CM, Schmidt SD, Terio NB, Duff K, Beard M, Mathews PM, Nixon RA. Presenilin mutations in familial Alzheimer disease and transgenic mouse models accelerate neuronal lysosomal pathology. J Neuropathol Exp Neurol. 2004 Aug;63(8):821-30. PubMed.
- Yu WH, Kumar A, Peterhoff C, Shapiro Kulnane L, Uchiyama Y, Lamb BT, Cuervo AM, Nixon RA. Autophagic vacuoles are enriched in amyloid precursor protein-secretase activities: implications for beta-amyloid peptide over-production and localization in Alzheimer's disease. Int J Biochem Cell Biol. 2004 Dec;36(12):2531-40. PubMed.
- Cataldo AM, Petanceska S, Terio NB, Peterhoff CM, Durham R, Mercken M, Mehta PD, Buxbaum J, Haroutunian V, Nixon RA. Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome. Neurobiol Aging. 2004 Nov-Dec;25(10):1263-72. PubMed.
- Hashimoto M, Takenouchi T, Rockenstein E, Masliah E. Alpha-synuclein up-regulates expression of caveolin-1 and down-regulates extracellular signal-regulated kinase activity in B103 neuroblastoma cells: role in the pathogenesis of Parkinson's disease. J Neurochem. 2003 Jun;85(6):1468-79. PubMed.
- Trushina E, Dyer RB, Badger JD, Ure D, Eide L, Tran DD, Vrieze BT, Legendre-Guillemin V, McPherson PS, Mandavilli BS, Van Houten B, Zeitlin S, McNiven M, Aebersold R, Hayden M, Parisi JE, Seeberg E, Dragatsis I, Doyle K, Bender A, Chacko C, McMurray CT. Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol Cell Biol. 2004 Sep;24(18):8195-209. PubMed.
No Available Comments
Make a Comment
To make a comment you must login or register.